Table 1.
Overview of marketed medications targeting receptors related to itch and their modes of action.
| Target | Medication | Mode | Disease | References |
|---|---|---|---|---|
| H1R | Cetirizine,Desloratadine, Doxepin… | Antagonist | Urticaria | [115, 117] |
| H4R |
JNJ-39758979 ZPL-3893787 |
Antagonist | Atopic dermatitis | [120, 121] |
| MOR | Naloxone | Antagonist | Chronic pruritus | [124] |
| KOR |
Nalfurafine Difelikefalin |
Agonist | Uremic pruritus | [122, 125] |
| Calcium channel | Gabapentin, Pregabalin | Blocker |
Neuropathic pruritus Uremic pruritus |
[127–129] |
| Calcium phosphatase | Tacrolimus,Cyclosporine | Inhibitor | Atopic dermatitis | [130] |
| PDE4 | Crisaborole, OPA-15406 | Inhibitor |
Atopic dermatitis Psoriasis |
[137, 138] |
| JAK |
Delgocitinib,Ruxolitinib,Baricitinib Tofacitinib,Upadacitinib, Filgotinib,Ivarmacitinib, Brepocitinib, Deucravacitinib, Jaktinib,ATI-1777,CEE321, NDI-034858,QL-12001869 |
Inhibitor |
Atopic dermatitis Chronic eczema Lupus erythematosus Psoriasis Vitiligo |
[141–149] |